Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.71 Consensus Price Target from Analysts

Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) have been assigned a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $56.7143.

A number of equities analysts recently issued reports on IMCR shares. Weiss Ratings restated a “sell (e+)” rating on shares of Immunocore in a report on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research report on Monday, April 20th. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a report on Sunday. Finally, Zacks Research downgraded shares of Immunocore from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th.

Immunocore Stock Performance

Immunocore stock opened at $34.68 on Thursday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.18 and a quick ratio of 4.15. The firm has a market capitalization of $1.76 billion, a P/E ratio of -63.05 and a beta of 0.73. Immunocore has a 1-year low of $27.56 and a 1-year high of $40.71. The company’s 50-day moving average is $29.93 and its 200 day moving average is $31.28.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.51. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same quarter in the previous year, the business earned $0.10 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Research analysts forecast that Immunocore will post 0.06 EPS for the current year.

Hedge Funds Weigh In On Immunocore

A number of institutional investors have recently modified their holdings of the stock. Primecap Management Co. CA grew its holdings in Immunocore by 5.5% during the 4th quarter. Primecap Management Co. CA now owns 3,961,880 shares of the company’s stock worth $137,517,000 after acquiring an additional 207,320 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Immunocore by 14.5% in the 3rd quarter. Bellevue Group AG now owns 2,796,803 shares of the company’s stock valued at $101,608,000 after purchasing an additional 354,973 shares in the last quarter. Tang Capital Management LLC lifted its position in shares of Immunocore by 14.0% in the 4th quarter. Tang Capital Management LLC now owns 2,628,538 shares of the company’s stock worth $91,237,000 after purchasing an additional 322,930 shares during the period. Millennium Management LLC boosted its stake in shares of Immunocore by 334.3% during the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after purchasing an additional 974,463 shares in the last quarter. Finally, Armistice Capital LLC increased its holdings in Immunocore by 33.3% during the fourth quarter. Armistice Capital LLC now owns 1,098,000 shares of the company’s stock valued at $38,112,000 after buying an additional 274,000 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.